Prosonix elects Ken Cunningham to board
This article was originally published in Scrip
Prosonix, a pharmaceutical company developing a portfolio of respiratory medicines, has elected Dr Ken Cunningham to its board of directors as a non-executive director, and chair of its advisory board. Dr Cunningham is executive chairman of PolyTherics and until August 2010 was CEO of Skyepharma.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.